Clinical Trial ResultsEQ101 initial proof-of-concept data prove positive.
Financial ImpactIf Ono exercises its option, this would result in a payment of ¥5B—roughly $32.2M based on recent exchange rates—and significantly improve Equillium's balance sheet strength.
Safety ProfileEQ101 was well-tolerated with no serious adverse events and no notable changes in safety laboratory, electrocardiogram, vital signs, or physical exam findings were reported.